High accuracy in predicting risk of age-related macular degeneration (AMD) disease progression.
The RetnaGene AMD test is designed to evaluate the risk of early or intermediate AMD progressing to advanced choroidal neovascular disease within 2, 5, and 10 years.
Safe. Noninvasive. Accurate.
The RetnaGene AMD test is a safe and highly accurate genetic test that uses a small DNA sample collected from a buccal (cheek) swab.
RetnaGene AMD test accuracy and reliability is backed by science:
- The only test to date to specifically predict the progression of early AMD to choroidal neovascularization (CNV).
- The only test to date that analyzes the four most clinically-relevant forms of the complement factor H gene, with high reporting accuracy.
- The only test to date supported with a peer reviewed validation study performed in its own CLIA-certified laboratory.
- The shortest test result turnaround time to date and access to a HIPPA-compliant physician portal for integration into EMR.
About Age-related Macular Degeneration.
AMD is an insidious, progressive eye disorder that starts with relatively harmless tiny yellow deposits on the retina (the light sensitive tissue in the eye) and increases in prevalence and severity with age. Geographic atrophy is considered the late stage of the dry form of AMD. Another advanced form of AMD is neovascular or 'wet AMD', which develops in 10 to 20% of all cases, causes profound loss of central vision and is the leading source of legal blindness in people over age 50 in the developed world. Wet AMD is caused by abnormal growth of fragile and leaky blood vessels, known as choroidal neovascularization in the macula (a small area where vision is keenest at the center of the retina) in response to chronic inflammatory stress.
Incidence of AMD.
AMD is the most common cause of visual impairment and the leading cause of blindness in the elderly population in the developed world. It is estimated that there are currently 9.1 million patients in the USA with AMD, 1.7 million suffering with the vision-threatening late stage complications of choroidal neovascularization or geographic atrophy. Moreover, it is predicted that the number of cases of early AMD will increase to 17.8 million by 2050 and if untreated, cases of late-stage blinding AMD will increase to 3.8 million.